Gene-edited crops pioneer Calyxt crashes, giving the lie to deregulation claims
By Jonathan Matthews and Claire Robinson,
GMWatch
| 10. 02. 2022
Kelly Sikkema for Unsplash
As governments around the world are lobbied by industry with claims gene editing can deliver rapid solutions to our food and farming problems — they just need deregulation, the company that pioneered gene-edited crops in the lax regulatory environment of the US is considering selling its assets amid plummeting revenues and share prices.
Calyxt was the first to market gene-edited soybeans in 2019. The beans are genetically engineered to produce high oleic oil. You might think anyone wanting high oleic oils could just buy olive oil but Calyxt was primarily targeting the processed foods markets by promoting its oil as a healthier alternative to commodity soybean oils that produce trans fats when cooked at high temperatures, though no research directly showed health benefits.
Calyxt was also reported to have other “consumer-focused” gene-edited foods in the pipeline, like high fibre wheat and reduced browning potatoes.
Rapidly developing disruptive technology
The company told investors that as a gene editing pioneer accelerating product development, “this is an exciting time for Calyxt and a rapidly developing disruptive plant-based technology story”...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...